Klaria receives 25 MSEK in loan financing with the possibility of an additional 15 MSEK
What's the deal? Klaria Pharma Holding, a Swedish listed pharma company, has secured a 25M SEK bridge loan from a Swedish finance company. The agreement includes an option to borrow an additional 15M SEK, bringing the total possible financing to 40M SEK.
The loan will be disbursed immediately and runs until May 27, 2027. It carries an arrangement fee of 1.5M SEK and a fixed interest rate of 30-day Stibor plus 1.5 percentage points.
Klaria develops rapid-acting drug delivery products using a patented oral film technology. It is listed on Nasdaq First North Growth Markets.
Why now? The financing is meant to strengthen Klaria's financial flexibility while it works with BDO London on a process to access markets worldwide. At the same time, its licensing partner CNX TherapeuticsDealroom has a profile for this one. Try Dealroom → is preparing to launch Sumatriptan Alginate Film in Europe, with large-scale manufacturing already underway.
"This financing significantly strengthens our flexibility, thus creating stability during the process we are now conducting together with BDO," said chairman Fredrik Hübinette.
What could go wrong? Bridge loans are short-term instruments, and the clock is ticking — Klaria has less than a year to either repay or refinance. Taking on debt with fees and interest adds pressure on a company that hasn't yet launched its flagship product commercially.
The European launch of Sumatriptan Alginate Film still depends on CNX Therapeutics hitting its milestones. Any delays could undermine the rationale for the loan.
The signal: Klaria's decision to take on a bridge loan at relatively steep terms underscores the funding pressures facing pre-revenue, listed pharma companies as they attempt to cross the gap from clinical development to commercial launch. With the BDO London process aimed at unlocking global markets, the company is effectively betting that near-term deal flow — whether through licensing, partnerships, or a broader capital raise — will materialise before the loan matures in May 2027.
Read more: news.cision.com
